Aktienanalyse zu Halozyme Therapeutics Inc (HALO)HALOHalozyme Therapeutics Inc

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Halozyme Therapeutics Inc is a good buy right now due to its strong revenue growth and positive earnings outlook. The current price is $105.35, and the company reported a 48% year-over-year revenue increase to $480.99 million in Q2 2026. Additionally, the forward P/E ratio is 14.53, indicating attractive valuation compared to future earnings potential. However, a risk to consider is the significant increase in hedge fund selling, which has risen by 4215.85% over the last quarter, suggesting caution in market sentiment.

10 analysts cover HALO: 7 rate it Buy, 2 Hold and 1 Sell. The average price target is 78.50.